Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
June 3, 2019 Off

Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics,…

June 3, 2019 Off

LYNPARZA® (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy

By BusinessWire

AstraZeneca and Merck’s LYNPARZA Increased the Median Time Without Disease Progression or Death by 4.2 Months Versus Physician’s Choice of…

June 3, 2019 Off

Largest Shareholder of Aurinia Pharmaceuticals, ILJIN SNT, Files Proxy Circular and Issues Letter to Fellow Shareholders

By BusinessWire

Three Independent Directors Nominated to Strengthen Board, Remove Conflicts and Return Control of the Company to Shareholders Commercial Potential of…

June 3, 2019 Off

Brooklyn ImmunoTherapeutics Announces Presentation of Ongoing Investigator Sponsored Trial of IRX-2 Regimen Combined with Nivolumab in Recurrent/Metastatic Solid Tumors

By BusinessWire

BROOKLYN, N.Y.–(BUSINESS WIRE)–Brooklyn ImmunoTherapeutics, a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients…

June 3, 2019 Off

NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients

By BusinessWire

First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting CD16 and CD19 in patients…

June 3, 2019 Off

Five-Year Survival Observed in Longest Follow-up to Date of Advanced Melanoma Patients Treated with the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab)

By BusinessWire

Five-year follow-up analysis from Phase 1 CA209-004 study provides evidence of long-term survival following discontinuation of treatment in patients with…

June 3, 2019 Off

Bio-Rad to Participate in Goldman Sachs Annual Global Healthcare Conference on June 11

By BusinessWire

HERCULES, Calif.–(BUSINESS WIRE)–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products,…

June 3, 2019 Off

Pharmaceutical Industry Invests in the Development of Early Clinical Research in Quebec

By BusinessWire

CATALIS’s public and private partners join forces to make Quebec a global leader in the conduct of early-stage clinical trials.…

June 3, 2019 Off

Managed Healthcare Executive® Pharmacy Survey Probes Strategies to Reduce Pharmaceutical Drug Costs

By BusinessWire

More than 34% of survey participants agreed that enhanced point-of-prescribing tools to assist prescriber in identification is the most effective…

June 3, 2019 Off

New Direction for Communications and Public Affairs for BIO

By BusinessWire

Veteran Public Affairs Campaign Executive Rich Masters to Join BIO in New Senior Position WASHINGTON–(BUSINESS WIRE)–BIO President & CEO Jim…

Posts pagination

Previous 1 … 3,136 3,137 3,138 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine